PCRX (Pacira BioSciences) Long-Term Capital Lease Obligation : $43.7 Mil (As of Mar. 2025)

View and export this data going back to 2011. Start your Free Trial

What is Pacira BioSciences Long-Term Capital Lease Obligation?

Pacira BioSciences's Long-Term Capital Lease Obligation for the quarter that ended in Mar. 2025 was $43.7 Mil.

Pacira BioSciences's quarterly Long-Term Capital Lease Obligation declined from Sep. 2024 ($47.9 Mil) to Dec. 2024 ($44.6 Mil) and declined from Dec. 2024 ($44.6 Mil) to Mar. 2025 ($43.7 Mil).

Pacira BioSciences's annual Long-Term Capital Lease Obligation declined from Dec. 2022 ($64.8 Mil) to Dec. 2023 ($54.8 Mil) and declined from Dec. 2023 ($54.8 Mil) to Dec. 2024 ($44.6 Mil).

Pacira BioSciences Long-Term Capital Lease Obligation Historical Data

The historical data trend for Pacira BioSciences's Long-Term Capital Lease Obligation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Pacira BioSciences Long-Term Capital Lease Obligation Chart

Pacira BioSciences Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Long-Term Capital Lease Obligation

Get a 7-Day Free Trial

71.03

71.73

64.80

54.81

44.65

Pacira BioSciences Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Long-Term Capital Lease Obligation	Get a 7-Day Free Trial															52.45	50.15	47.88	44.65	43.68

Pacira BioSciences (NAS:PCRX) Long-Term Capital Lease Obligation Explanation

Long-Term Capital Lease Obligation are the amount due for long-term asset lease agreements that are nearly equivalent to asset purchases. Capital lease obligations are installment payments that constitute a payment of principal plus interest for the capital lease. The Short-Term Capital Lease Obligation is the portion of a Long-Term Capital Lease Obligation that is due over the next year.

Under US Generally Accepted Accounting Principles (GAAP), a capital lease is essentially equivalent to a purchase by the lessee if it meets the following criteria:

1. Ownership of the asset is transferred to the lessee at the end of the lease term;
2. The lease contains a bargain purchase option to buy the equipment at less than fair market value;
3. The lease term equals or exceeds 75% of the asset's estimated useful life;
4. The present value of the lease payments equals or exceeds 90% of the total original cost of the equipment.

Pacira BioSciences Long-Term Capital Lease Obligation Related Terms

Thank you for viewing the detailed overview of Pacira BioSciences's Long-Term Capital Lease Obligation provided by GuruFocus.com. Please click on the following links to see related term pages.

Pacira BioSciences Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Pacira BioSciences Inc (NAS:PCRX) » Definitions » Long-Term Capital Lease Obligation

Comparable Companies

Traded in Other Exchanges

82P:Germany

Address

5401 West Kennedy Boulevard, Suite 890, Tampa, FL, USA, 33609

Website

https://www.pacira.com

Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.

Executives

Jonathan Slonin	officer: Chief Clinical Officer	C/O PACIRA BIOSCIENCES, INC., 5 SYLVAN WAY, SUITE 300, PARSIPPANY NJ 07054
Daryl Gaugler	officer: Chief Operating Officer	C/O PACIRA BIOSCIENCES, INC., 5 SYLVAN WAY, SUITE 300, PARSIPPANY NJ 07054
Marcelo Bigal	director	C/O PACIRA BIOSCIENCES, INC., 5401 WEST KENNEDY BOULEVARD, SUITE 890, TAMPA FL 33609
Laura Brege	director	C/O ONYX PHARMACEUTICALS, INC., 2100 POWELL STREET, EMERYVILLE CA 94608
Michael J. Yang	director	C/O ACADIA PHARMACEUTICALS INC., 12830 EL CAMINO REAL, SUITE 400, SAN DIEGO CA 92130
Mark Froimson	director	5 SYLVAN WAY, SUITE 300, PARSIPPANY NJ 07054
Kristen Marie Williams	officer: CAO and General Counsel	C/O PACIRA PHARMACEUTICALS, INC., 5 SYLVAN WAY, SUITE 300, PARSIPPANY NJ 07054
Paul J Hastings	director	61 HARTFORD STREET, SAN FRANCISCO CA 94114
Lauren Bullaro Riker	officer: Executive Director, Accounting	C/O PACIRA PHARMACEUTICALS, INC., 5 SYLVAN WAY, PARSIPPANY NJ 07054
Gary W Pace	director	C/O RESMED INC, 14040 DANIELSON STREET, POWAY CA 92064-6857
Alethia Young	director	C/O GRAPHITE BIO, INC., 201 HASKINS WAY, SUITE 210, SOUTH SAN FRANCISCO CA 94080
Abraham Ceesay	director	C/O SCPHARMACEUTICALS, INC., 2400 DISTRICT AVENUE SUITE 310, BURLINGTON MA 01830
Roy Winston	officer: Chief Clinical Officer	C/O PACIRA BIOSCIENCES, INC,, 5401 WEST KENNEDY BOULEVARD, SUITE 890, TAMPA FL 33609
Mark A. Kronenfeld	director	C/O PACIRA PHARMACEUTICALS, INC., 5 SYLVAN WAY, SUITE 100, PARSIPPANY NJ 07054
Reinhart Charles A. Iii	officer: Chief Financial Officer	C/O PACIRA PHARMACEUTICALS, INC., 5 SYLVAN WAY, SUITE 300, PARSIPPANY NJ 07054